References

Chapter 1

. Ichikawa, M.,et al. 1991. A new multiple-unit oral floating dosage system. II: In vivo

evaluation of floating and sustained-release characteristics with p-aminobenzoic acid

and isosorbide dinitrate as model drugs. J. Pharm. Sci. 80, 1153–1156.

2. Kawashima, Y.et. al., 1991. Preparation of multiple unit hollow microspheres

(microballoons) with acrylicresin containing tranilast and their drug release

characteristics (in vitro) and floating behavior (in vivo). J. Control. Release 16, 279–

290.

3. Atyabi, F. et. al., 1996. In vivo evaluation of novel gastric retentive formulation based

on ion exchange resins. J. Control. Release 42, 105–113.

4. Iannuccelli, V. et. al.,1998. Air compartment multiple-unit system for prolonged

gastric residence. Part II. In vivo evaluation. Int. J. Pharm. 174, 55–62.

5. Hwang, S.J. et. al., 1998. Gastric retentive drug-delivery systems. Crit. Rev. Ther.

Drug Carrier Syst. 15, 243–284.

6. Moës, A.J., 1993. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carrier Syst.

10, 143–195.

7. Deshpande, A. et. al., 1996. Controlled-release drug delivery systems for prolonged

gastric residence: overview. Drug Dev. Ind. Pharm. 22, 531–539.

8. Rouge, N. et. al., 1996. Drug absorption sites in gastrointestinal tract and dosage

forms for site-specific delivery. Int. J. Pharm. 136, 117–139.

9. Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: approach to oral

controlled drug delivery via gastric retention. J. Control. Release 63, 235–259.

10. Sheth, P.R., Tossounian, J.L., 1979a. Sustained release tablet formulations. U.S.

Patent 4,140,755.

11. Sheth, P.R., Tossounian, J.L., 1979b. Novel sustained release tablet formulations.

U.S. Patent 4,167,558.

12. Baumgartner, S. et. al., 2000. Optimisation of floating matrix tablets and evaluation

of their gastric residence time. Int. J. Pharm. 195, 125–135.

13. Colombo, P. et. al., 1989. The role of compression force in floating tablet formula

optimization. Acta Pharm. Technol. 35, 168–170.

14. Gerogiannis, V.S. et. al., 1993. Floating and swelling characteristics of various

excipients used in controlled release technology. Drug Dev. Ind. Pharm. 19, 1061–

1081.

15. Rouge, N. et. al., 1997. Screening of potentially floating excipients for minitablets.

STP Pharma Sci. 7, 386–392.

16. Baumgartner, S., Smid-Korbar, J.,Vrecer, F., Kristl, J., 1998. Physical and

technological parameters influencing floating properties of matrix tablets based on

cellulose ethers. STP Pharma Sci. 8, 285–290.

17. Ingani, H.M., Timmermans, J., Moës, A.J., 1987. Conception and in vivo

investigation of peroral sustained release floating dosage forms with enhanced

gastrointestinal transit. Int. J. Pharm. 35, 157–164.

18. Yang, L., Fassihi, R., 1996. Zero-order release kinetics from self- correcting floatable

asymmetric configuration drug delivery system. J. Pharm. Sci. 85, 170–173.

19. Yang, L., Eshraghi, J., Fassihi, R., 1999. A new intragastric delivery system for

treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation.

J. Control. Release 57, 215–222.

20. Timmermans, J., Moës, A.J., 1990. How well do floating dosage forms float? Int. J.

Pharm. 62, 207–216.

21. Müller,W., Anders, E., 1989. Floating system for oral therapy.WO Patent 89/06956.

22. Siepmann, J., Peppas, N.A., 2001. Modeling of drug release from delivery systems

based on hydroxypropyl methylcellulose. Adv. Drug Deliv. Rev. 48, 139–157.

23. Siepmann, J., Streubel, A., Peppas, N.A., 2002. Understanding and predicting drug

delivery from hydrophilic matrix tablets using ‘‘sequential layer’’ model. Pharm. Res.

19, 306–314.

24. Velasco, M.V., Ford, J.L., Rowe, P., Rajabi-Siahboomi, A.R., 1999. Influence of

drug: hydroxypropylmethylcellulose ratio, drug and polymer particle size and

compression force on release of diclofenac sodium from HPMC tablets. J.

Control. Release 57, 75–85.

25. Sung, K.C., Nixon, P.R., Skoug, J.W., Ju, T.R., Gao, P., Topp, E.M., Patel, M.V.,

1996. Effect of formulation variables on drug and polymer release from HPMC-based

matrix tablets. Int. J. Pharm. 142, 53–60.

26. Colombo, P., Conte, U., Gazzaniga, A., Maggi, L., Sangalli, M.E., Peppas, N.A., La

Manna, A., 1990. Drug release modulation by physical restrictions of matrix swelling.

Int. J. Pharm. 63, 43–48.

27. Conte, U., Maggi, L., Colombo, P., La Manna, A., 1993. Multi-layered hydrophilic

matrices as constant release devices (Geomatrix_ Systems). J. Control. Release 26,

39–47.

28. Desai S. A Novel Floating Controlled Release Drug Delivery System Based on Dried

Gel Matrix Metrix [master’s thesis]. [thesis]. Jamaica, NY: St John’s

University; 1984.

29. Vantrappen GR, Peeters TL, Janssens J. The secretory component of interdigestive

migratory motor complex in man. Scand J Gastroenterol. 1979; 14:663-667.

30. Wilson CG, Washington N. The stomach: its role in oral drug

delivery. In: Rubinstein MH, ed. Physiological Pharmacetical: Biological Barriers to

Drug Absorption. Chichester, UK: Ellis Horwood; 1989:47-70.

31. S Bolton, S Desai, Floating sustained release therapeutic compositions, US Patent,

4,814,179,March 21; 1989.

32. R C Mamajek, E S Moyer, Drug dispensing and method US patent 4,207,890, June

17; 1980 through C.A.1984 K50391.

33. L Whitehead, J T Fell J H Collett, Development of Gastroretentive Dosage Form.

European Journal of Pharmaceutical Sciences; 1996,4 (1): S182.

34. V Iannuccelli, G Coppi, R Sansone and G Ferolla, Aircompartment Multiple-unit

System for Prolonged GastricResidence, Part II. Invivo Evaluation.

InternationalJournal of Pharmaceutics; 1998,174 (1–2): 55–62.

35. N R Jimenez Castellanos, H Zia and C Rhodes, Mucoadhesive Drug Delivery

Systems. Drug Development and Industrial Pharmacy; 1993, 19: 143.

36. R Talukder and R Fissihi, Gastroretentive delivery systems: A mini review. Drug

Dev. Ind. Pharm.; 2004, 30 (10): 1019-1028.

37. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of novel controlled

release system for gastric retention. Pharm Res. 1997;14:815-819.

38. Burns SJ, Attwood D, Barnwell SG. Assesment of dissolution vessel designed for

use with floating and erodible dosage forms. Int. J. Pharm. 1998;160:213-218.

39. Joseph NJ, Laxmi S, Jayakrishnan A. A floating type oral dosage from for piroxicam

based on hollow microspheres: in vitro and in vivo evaluation in rabbits. J. Control

Release. 2002;79:71-79.

40. Sheth PR, Tossounian JL, inventors. Sustained release pharmaceutical capsules. US

patent 4,126,672. November 21, 1978.

41. Soppimath KS, Kulkarni AR, Rudzinski WE, Aminabhavi TM. Microspheres as

floating drug delivery system to increase gastric residence of drugs. Drug Metab

Rev. 2001;33:149-160.

42. Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage

system. I: Preparation and in vitro evaluation of floating and sustained-release

kinetics. J. Pharm. Sci. 1991;80:1062-1066.

43. Ichikawa M, Watanabe S, Miyake Y, inventors. Granule remaining in stomach. US

patent 4 844 905. July 4, 1989.

44. Ozdemir N, Ordu S, Ozkan Y. Studies of floating dosage forms of furosemide: in

vitro and in vivo evaluation of bilayer tablet formulation. Drug Dev. Ind.

Pharm. 2000;26:857-866.

45. Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for floating

drug delivery: effects of CO2 gas forming agents. Int. J. Pharm. 2002;239:81-91.

46. Li S, Lin S, Daggy BP, Mirchandani HL, Chien TW. Effect of formulation variables

on floating properties of gastric floating drug delivery system. Drug Dev. Ind.

Pharm. 2002;28:783-793.

47. Li S, Lin S, Chien TW, Daggy BP, Mirchandani HL. Statistical optimization of

gastric floating system for oral controlled delivery of calcium. AAPS

PharmSciTech. 2001;2:E1.

48. Penners G, Lustig K, Jorg PVG, inventors. Expandable pharmaceutical forms. US

patent 5 651 985. July 29, 1997.

49. Fassihi R, Yang L, inventors. Controlled release drug delivery systems. US patent 5

783 212. July 21, 1998.

50. Talwar N, Sen H, Staniforth JN, inventors. Orally administered controlled drug

delivery system providing temporal and spatial control. US patent 6 261

601. July 17, 2001.

51. Michaels AS, Bashwa JD, Zaffaroni A, inventors. Integrated device for administering

beneficial drug at programmed rate. US patent 3 901 232. August 26, 1975.

52. Michaels AS, inventor. Drug delivery device with self actuated mechanism for

retaining device in selected area. US patent 3 786 813. January 22, 1974.

53. Moursy NM, Afifi NN, Ghorab DM, El-Saharty Y. Formulation and evaluation of

sustained release floating capsules of Nicardipine HCl. Pharmazie. 2003;58:38-43.

54. Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained release drug delivery

systems using polycarbonate microspheres capable of floating on gastric fluids. J.

Pharm. Pharmacol. 1993;45:21-24.

55. Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: design and release

kinetics. Drug Dev. Ind. Pharm. 2000;26:965-969.

56. Bulgarelli E, Forni F, Bernabei MT. Effect of matrix composition and process

conditions on casein gelatin beads floating properties. Int. J. Pharm. 2000;198:157-

165.

57. Whitehead L, Collett JH, Fell JT. Amoxycillin release from floating dosage form

based on alginates. Int. J. Pharm. 2000;210:45-49.

58. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density

foam powder: effect of formulation and processing parameters on drug release. Eur J

Pharm Sci. 2003;18:37-45.

59. Asmussen B, Cremer K, Hoffmann HR, Ludwig K, Roreger M, inventors. Expandable

gastroretentive therapeutic system with controlled active substance release in

gastrointestinal tract. US patent 6 290 989. September 18, 2001.

60. El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and evaluation of

ketoprofen floating oral drug delivery system. Int J Pharm. 2001;220:13-21.

61. Illum L, Ping H, inventors. Gastroretentive controlled release microspheres for improved

drug delivery. US patent 6 207 197. March 27, 2001.

62. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density

foam powder. Int. J. Pharm. 2002;241:279-292.

63. Ushomaru K, Nakachimi K, Saito H, inventors. Pharmaceutical preparations and

method of manufacturing them. US patent 4 702 918. October 27, 1987.

64. Dennis A, Timminis P, Lel K, inventors. Buoyant controlled release powder

formulation. US patent 5 169 638. December 8, 1992.

65. Spickett RGW, Vidal JLF, Escoi JC, inventors. Antacid preparation having prolonged

gastric residence. US patent 5,288,506. February 22, 1993.

66. Franz MR, Oth MP, inventors. Sustained release, bilayer buoyant dosage form. US

patent 5 232 704. August 3, 1993.

67. Wu W, Zhou Q, Zhang HB, Ma GD, Fu CD. Studies on nimodipine sustained release

tablet capable of floating on gastric fluids with prolonged gastric resident time. Yao

Xue Xue Bao. 1997;32:786-790.

68. Wong PSL, Dong LC, Edgren DE, Theeuwes F, inventors. Prolonged release active

agent dosage form adapted for gastric retention. US patent 6 120

803. September 19, 2000.

69. Mitra SB, inventor. Sustained release oral medicinal delivery device. US patent 4 451

260. May 29, 1984.

70. Harrigan BM, inventor. Drug delivery device for preventing contact of undissolved

drug with stomach lining. US patent 4 055 178. October 25, 1977.

71. Garima Chawla, Piyush Gupta, Vishal Koradia and Arvind K Bansal, Gastroretention:

A means to address regional variability in intestinal drug absorption. Pharmaceutical

technology; 2003,27(2):50-68.

72. Hetal N Kikani, A Thesis on, Floating drug delivery system, The North Gujarat

University, Patan; 2000-2001: 11-12.

73. Garg S, Sharma S. Gastroretentive drug delivery systems. Business Briefing:

Pharmatech 2003 Web Site. 5th edition. May 2003 Available at:

http://www.touchbriefings.com/cdps/cditem.cfm?NID=17&CID=5. Accessed

October 6, 2005.

74. S Sangekar, Evaluation of effect of food and specific gravity of tablets on gastric

retention time. Int. J. Pharm.; 1990,35(3): 34-53.

75. Xu WL, Tu XD, Lu ZD, Development of Gentamycin sulfate sustained-release tablets

remaining-floating in stomach.; 1991, 26(7): 541-545.

76. Mojaverian P, Ferguson RK, Vlasses PH, et al. Estimation of gastric residence time

of Heidelberg capsules in humans: effect of varying food

composition. Gastroenterology. 1985;89:392-397.

77. P Mojaverian, P H Vlasses, P E Kellner and M L Rocci, Effects of gender, posture,

and age on gastric residence time of indigestible solid: pharmaceutical considerations.

Pharm. Res.; 1998, 10:639–64.

78. N K Jain, Progress in controlled and novel drug delivery systems, First Ed.;

2004,CBS Publishers and Distributors, New Delhi, Bangalore: 84-85.

79. Timmermans J, Andre JM. Factors controlling buoyancy and gastric retention

capabilities of floating matrix capsules: new data for reconsidering controversy. J.

Pharm Sci. 1994;83:18-24.

80. Timmermans J, Gansbeke VB, Moes AJ. Assessing by gamma scintigraphy in vivo

buoyancy of dosage forms having known size and floating force profiles as function

of time. Vol I. Paris, France: APGI; 1989. 42-51.

81. J Timmermans and A J Moes, Measuring resulting weight of immersed tests material

II: Examnples of kinetic determination applied for monolithic dosage forms.

Acta.Pharma.Technol.; 1990,36(1):176-180.

82. Babu VBM, Khar RK. In vitro and In vivo studies of sustained release floating

dosage forms containing salbutamol sulphate. Pharmazie. 1990;45:268-270.

83. H G Shivkumar, D Vishakante Gwdaand T M Pramod Kumar, Floating controlled

drug delivery systems for prolong gastric residence. Indian J. Pharm. Edu.; 2004, 38

(4): 172-179.

84. Fell J T, Whitehead L, Collet H, Prolonged gastric retention using floating dosage

forms. Pharm Technology.; 2000,24(3): 82-90.

85. Hilton AK, Deasy PB, In vitro and in vivo evaluation of oral sustained-release

floating dosage form of amoxicillin trihydrate. Int J Pharm.; 1992,86(10): 79-88.

86. A J Moës, Gastric Retention Systems for Oral Drug Delivery. Business Briefing,

Drug Delivery Oral, Pharmtech; 2003:158-159.

1. James E F Reynolds: Martindale, The extra Pharmacopoeia, Thirty-First edition,

Royal Pharmaceutical Society, London; 1996: 901 - 902.

2. The United States Pharmacopoeia 26 /The National Formulary 21, Ranitidine

Hydrochloride, United States Pharmacopeial Convention, Inc,: 1615 – 1619.

3. Monograph<R, Clarke's Analysis of Drugs and Poisons,

http://www.medicinescomplete.com/mc/clarke/2006/

4. Ranitidine, http://www.drugs.com

5. Goodman & Gilman’s The pharmacological basis of therapeutics. Eleventh

edition. Brunton Laurence L., Lazo John S., Parker Keith L:Mc Graw Hill

Medical publication divison; 971-972, 1866.

6. Zantac Product information, GlaxoWellcome Inc.

7. Histamine H2 antagonists. In: Drug Facts and Comparisons. Fifty Sixth edition. St

Louis, MO: Wolters Kluwer Co; 2002:1192-1197.

8. British Pharmacopoeia 2005, Ranitidine, The Stationery Office on behalf of

Medicines and Healthcare products Regulatory Agency (MHRA): 1714 – 1716.

9. Indian Pharmacopoeia 1996, Ranitidine hydrochloride, The Controller of

Publications, Delhi © Govt. of India Ministry of Health and Family Welfare: 659-

661.

1. Raymond, C.R., 2003. Handbook of Pharmaceutical Excipients; American

Pharmaceutical association ,4th Edition,462-468

2. www.pharma-polymers.com

3. www.roehm.com

4. www.pformulate.com

5. www.corel Pharm chem.com

6. Vyas, S.P., Khar,R.K., 2002. Targeted and controlled drug delivery: novel carrier

systems ; CBS publication 1sr edition;417-430

7. Soppimath, K.S., Kulkarni, A.R., Rudzinski, W.E., 2001. Microspheres as floating

drug delivery system to increase gastric residence of drugs. Drug Metab Rev.

33,149-160.

8. Lee, J.H., Park, T.G., Choi, H.K., 1999. Development of oral drug delivery system

using floating microspheres. J Microencapsul. 16, 715-729.

9. KIM, B. K., Park, H. J., 2002. Preparation and evaluation of microspheres with

acrylic polymers by oil-in-oil emulsion solvent evaporation method: Annual

Meeting and Food Expo Anaheim, California.

10. Streubel, A., Siepmann, J., 2003. Multiple unit gastroretentive drug delivery

systems: new preparation method for low density microparticles. J Microencapsul.

20, 329-347.

11. Mathiowitz, E., 1999. Encyclopedia of controlled drug delivery, vol-1, New York:

John Wiley, 9-11.

12. Whitehead, L., Fell, J.T., Sharma, H.L., 1998. In vivo study demonstrating

prolonged gastric retention. J. Control Rel. 55,3-12.

13. Singh, B.N., Kim, K.H., 2000. Floating Drug Delivery Systems: An Approach to

Oral Controlled Drug Delivery via Gastric Retention. J. Control Rel. 63, 235-259.

14. Machida, Y., Inouye, K., 1989. Preparation and Evaluation of Intra gastric Buoyant

Preparations. Drug Des. Del. 4,155–161.

15. Gruber, P., 1987. Gastric Emptying of Non digestible Solids in Fasted Dog. J.

Pharm. Sci. 76, 117–122.

16. Sheth, P.R., Tossounian, J., 1984. The Hydro-dynamically Balanced System: A

Novel Drug Delivery System for Oral Use. Drug Dev. Ind. Pharm.10, 313–339.

17. Watanabe, S., 1976. Solid Therapeutic Preparation Remaining in Stomach. US

Patent 3 976 764. 24 August.

18. Michaels,A.S., Bashwa, J.D., 1975. Integrated Device for Administering Bene

ficialDrug at Programmed Rate. US Patent 3 901 232. 26 August.

19. Chang, H.S., 1985. Bioadhesive Polymers as Platforms for Oral Controlled Drug

Delivery II: Synthesis and Evaluation of Some Swelling, Water-Insoluble

Bioadhesive Polymers. J. Pharm. Sci. 74, 399–405

20. Davis, D.W., 1968. Method of Swallowing Pill. US Patent 3 418 999. 31 December.

21. Ichikawa, M., Watanabe, S., Miyake, Y., 1991. A New Multiple Unit Oral Floating

Dosage Systems, I: Preparation and In Vitro Evaluation of Floating and Sustained

Release Characteristics. J. Pharm. Sci. 80, 1062–1066

22. Mitra, S.B., 1984, Sustained Release Oral Medicinal Delivery Device. US Patent 4

451 260. 29 May.

23. Kawashima, Y., 1992. Hollow Microspheres for Use as Floating Controlled Drug

Delivery System in Stomach. J. Pharm. Sci.81, 135–140.

24. Fell, J.T., Whitehead, L., Collett, J.H., 2000. Prolonged Gastric Retention Using

Floating Dosage Forms Pharm. Technol. 82–90.

25. Iannuccelli, V., 1998. Air Compartment Multiple-Unit Systems for Prolonged

Gastric Residence Part I: Formulation Study. Int. J. Pharm. 174, 47–54.

26. Sakr, F.M., 1999. A Programmable Drug Delivery System for Oral Administration.

Int. J. Pharm. 184, 131–139.

27. Michaels, A.S., 1974. Drug Delivery Device with Self-Actuated Mechanism for

Retaining Device in Selected Area. US Patent 3 786 813. 22 January.

28. Michaels, A.S., Bashwa, J.D., Zaffaroni, A., 1975. Integrated Device for

Administering Beneficial Drug at Programmed Rate. US Patent 3 901 232. 26

August.

29. Hilton, A.K., Deasy, P.B., 1992. In Vitro and In Vivo Evaluation of Oral Sustained-

Release Floating Dosage Form of Amoxycillin Trihydrate. Int. J. Pharm. 86, 79–88.

30. Sheth, P.R., Tossounian, J.L., 1979. Novel Sustained Release Tablet

Formulations.US Patent 4 167 558

31. Sheth, P.R., Tossounian, J., 1984. The Hydrodynamically Balanced System: A

Novel Drug Delivery System for Oral Use. Drug Dev. Ind.Pharm. 10, 313–339.

32. Gupta, P.K., Robinson, J.R., 1992. Oral Controlled Release Delivery in Treatise on

Controlled Drug Delivery, A. Kydonieus, Eds. Marcel Dekker, New Jersey, 255–

310.

33. Seng, C.H., 1985. Bioadhesive Polymers as Platforms for Oral Controlled Drug

Delivery II—Synthesis and Evaluation of Some Swelling, Water-Insoluble

Bioadhesive Polymers. J. Pharm. Sci. 74, 399–405.

34. Park, K., Robinson, J.R., 1984. Bioadhesive Polymers as Platforms for Oral

Controlled Drug Delivery: Method to Study Bioadhesion. Int. J. Pharm. 19, 107–

127.

35. Chien, Y.W., 1992. Oral Drug Delivery Systems, in Novel Drug Delivery Systems,

Marcel Dekker, New York, 139–196.

36. Lehr, C.M., Hass, J., 2002. Developments in Area of Bioadhesive Drug Delivery

Systems. Expert Opinion on Biological Therapy 2, 287–298.

37. Caldwell, L.J., Gardner, C.R., Cargill, R.C., 1988. Drug Delivery Device Which

Can Be Retained in Stomach for Controlled Period of Time. US Patent 4 735 804. 5

April.

38. Gupta, P., Vermani, K., Garg, S., 2002. Hydrogels: From Controlled Release to pH-

Responsive Drug Delivery. Drug Discov. Today 7, 569–579.

39. Deshpande, A.A., 1997. Development of Novel Controlled-Release System for

Gastric Retention Pharm. Res. 14, 815–819.

40. Devereux, J.E., Newton, J.M., Short, M.B., 1990. The Influence of Density on

Gastrointestinal Transit of Pellets. J. Pharm. Pharmacol. 42, 500–501

41. Clarke, G.M., Newton, J.M., Short, M.B., 1995. Comparative Gastrointestinal

Transit of Pellet Systems of Varying Density. Int. J. Pharm.114, 1–11.

42. Thanoo, A.C., Sunny, M.C., Jaykrishnan, A., 1993. Oral sustained release drug

delivery systems using polycarbonate microspheres capable of floating on gastric

fluid. J. Pharm. Pharmacol. 45, 21-24.

43. Talukder, R., 2004. Gastroretentiver delivery systems: mini review drug dev. Ind.

Pharm.,30, 1019-1028.

44. Baumgartner, S., Kristel, J., Vreer, F., 2000. Optimisation of floating matrix tablets

and evaluation of their gastric residence time. Int. J. Pharm. 195, 125-135.

45. Sheth, P.R., Tossounian, J., 1984. The hydrodynamically balanced systems (HBS):

novel drug delivery system for oral use. Drug Dev Ind. Pharm.10, 313-339.

46. Menon, A., Ritschel, W.A., Sakr, A., 1994. Development and evaluation of

monolithic floating dosage form for furosemide. J Pharm Sci. 83, 239-245.

47. Phuapradit, W., Bolton, S., 1991. Influence of tablet density on oral absorption of

sustained release acetaminophen matrix tablets. Drug Dev Ind Pharm. 17, 1097-

1107.

48. Kedzierewicz, F., Thouvenot, P., Lemut, J., Etienne, A., 1999. Evaluation of peroral

silicone dosage forms in humans by gammascintigraphy. J. Control Release. 58,

195-205.

49. Groning, R., Heun, G., 1984. Oral dosage forms with controlled gastrointestinal

transit. Drug Dev Ind Pharm.10,527-539.

50. Groning, R., Heun, G., 1989. Dosage forms with controlled gastrointestinal passage

studies on absorption of nitrofurantion. Int J Pharm. 56, 111-116.

51. Ichikawa, M., Watanabe, S., Miyake, Y., 1991. A new multiple-unit oral floating

dosage system. II: In vivo evaluation of floating and sustained-release

characteristics with para amino benzoic acid and isosorbide dinitrate as model

drugs. J. Pharm. Sci. 80, 1153-1156.

52. Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: approach to oral

controlled drug delivery via gastric retention. J Control Release 63, 235-259.

53. Timmermans, J., Andre, J,M., 1994. Factors controlling buoyancy and gastric

retention capabilities of floating matrix capsules: new data for reconsidering

controversy. J. Pharm. Sci. 83, 18-24.

54. Garg, S., Sharma, S., 2003. Gastroretentive drug delivery systems. Business

Briefing Pharmatech.

55. Joseph, N.J., Laxmi, S., Jayakrishnan, A., 2002. A floating type oral dosage from

for piroxicam based on hollow microspheres: in vitro and in vivo evaluation in

rabbits. J. Control Release.79, 71-79.

56. Dennis, A., Timminis, P., Lel, K., 1992. Buoyant controlled release powder

formulation. US patent 5 169 638. 8 December.

57. Burns, S.J., Attwood, D., Barnwell, S.G., 1998. Assesment of dissolution vessel

designed for use with floating and erodible dosage forms. Int J Pharm. 160, 213-

218.

58. Yang, L., Esharghi, J., Fassihi, R., 1999. A new intra gastric delivery system for

treatment of helicobacter pylori associated gastric ulcers: in vitro evaluation. J

Control Release. 57, 215-222.

59. Gibaly, E.I., 2002. Development and evaluation of novel floating chitosan

microcapsules: comparision with non floating chitosan microspheres. Int J

Pharm.249, 39-47.

60. Sato, Y., Kawashima, Y., 2003. In vitro and in vivo evaluation of riboflavin

containing microballoons for floating controlled drug delivery system in healthy

human volunteers. J Control Release. 93, 39-47.

61. Shimpi, S., Chauhan, B., Mahadik, K.R., Paradkar, A., 2004. Preparation and

evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by

melt granulation. AAPS Pharm Sci Tech 5, E43.

62. Dave, B.S., Amin, A.F., Patel, M.M., 2004. Gastroretentive drug delivery system of

ranitidine hydrochloride: formulation and in vitro evaluation. AAPS Pharm Sci

Tech. 5, E34.

63. Sriamornsak, P., Thirawong, N., Puttipipatkhachorn, S., 2004. Morphology and

buoyancy of oil entrapped calcium pectinate gel beads. AAPS Pharm Sci Tech 6,

E24.

64. Shweta, A., Ali, J., Khar, R.K., 2005. Floating Drug Delivery Systems: A Review.

AAPS Pharm SciTech. 6, E372-E790.

65. Illum, L., Ping, H., 2001. Gastroretentive controlled release microspheres for

improved drug delivery. US patent 6 207 197. 27March.

66. www. drugs.com

Chapter 2

Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: approach to oral controlled drug

delivery via gastric retention. J. Control. Release 63, 235–259.

2. Dave BS, Amin AF, Patel MM. 2004. Gastroretentive Drug Delivery System of Ranitidine

Hydrochloride: Formulation and In Vitro Evaluation. AAPS Pharm Sci Tech., 5(2), article

34.

3. Soppimath KS, Kulkarni AR, Rudzinski WE, Aminabhavi TM. 2001. Microspheres as

floating drug-delivery systems to increase gastric retention of drugs. Drug Metab Rev., 33(2),

149-160.

4. Baumgartner S, Krsti J, Zorko B, 2000. Optimisation of floating matrix tabletand evaluation

of gastric recidence time. Int. J. Pharm., 195(1), 125-135.

5. Shimpi S, Chauhan B, Mahadik K R, Paradkar P, 2004. Preparation and Evaluation of

Diltiazem Hydrochloride-Gelucire 43/01 Floating Granules Prepared by Melt Granulation.

AAPS Pharm Sci Tech., 5(3), 19-25.

6. Stockwell A F, Davis S S, Walker S E, In vitro evaluation of alginate gel systems as sustained

release drug delivery systems. J.Control.Release; 1986, 3: 167-175.

7. Igani H M, Timmermans J, Moes A J, 1987. Conception and in vitro investigation of peroral

sustained release dosage forms with enhanced gastrointestinal transit. Int. J. Pharm., 35, 157-

164.

8. Sheth P R, Tossounian J L, Sustained release pharmaceutical capsules, US patent,

4,126,672,November 21; 1978.

9. Sangejkar W, A Vadino, I Chaudary, A Parr, R Beihn, G Digenis, 1987. Evaluation of effect

of food and specific gravity of tablets on gastric retention time. Int. J. Pharm., 35, 187-191.

10. Nakamichi K, Yasuura H, Fukui H, Oka M, Izumi S, 2001. Evaluation of floating dosage

form of Nicardipine Hydrochloride and Hydroxy propyl methyl cellulose acetate succinate

prepared using twin-screw extruder. Int. J. Pharm., May 7, 218(1-2), 103-112.

11. Fabregas J L, Claramunt J, Cucala J, Pous R, Siles A, 1994. In vitro testing of antcid

formulation with prolong gastric residence time (Amalgate Flot-Coat), Drug. Dev. Ind.

Pharm., 20, 1199-1212.

12. Mazer N, Abisch E, Glffeler J C, Laplanche R, Bauer-frind P, Cucala M, Lukachick M, Blum

A, 1988. Intra gastric gastrointestinal behavior and absorption kinetic of normal and floating

modified release capsule of Iseradipine under fasted and fed conditions. J. Pharm. Sci., 89,

647-657.

13. Inouye K, Machida Y, Sanna T, Nagai T, 1988, Buoyant sustained release tablets based on

chitosan. Drugs Des. Del., 2, 165-175.

14. Kawashima Y, Niwa T, Tekeuchi H, Hino T, Itoh Y, 1992. Hollow microspheres for use as

floating controlled drug delivery system in stomach. J. Pharm. Sci., 81, 135-140.

15. Franz M R, Oth M P, Sustained release bilayer buoyant dosage form, US patent, 5,232,704,

August 3; 1993.

16. Desai S, Bolton S, 1993. A floating controlled drug delivery systems: In vitro in vivo

evaluation. Pharm. Res., 10, 1321-1325.

17. Du Quing, Fan Chum Sun, 1996. Preparation and evaluation of floating granules of

Aminophyllin. Through Chemical Abstract, 125(3), 6745u.

18. Whitehead L, Collette H, 2000. Prolong Gastric retention using floating dosage form. Pharm.

Tech., 3, 82-90.

19. Nur AO, Zhang JS, 2000. Captopril floating /or bioadhesive tablet: Design and release

kinetic. Drug. Dev. Ind. Pharm., 26(9), 965-970.

20. Shoufeng L, 2001. Stastastical Optimization of gastric floating system for oral controlled

delivery of calcium. AAPS Pharm. Sci. Tech., 2(1), 1-10.

21. Farouk M, 1999. A programmable drug delivery system for oral administration. Int. J.

Pharm., 184, 131-139.

22. Talwar N, Sen H, Orally administered controlled drug delivery system providing temporal

and spatial control, WO Patent, 151198; 2000.

23. Joseph N J, Lakshmi S, Jayakrishnan.A A A, 2002. A floating-type oral dosage form for

Piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in

rabbits, J. Controlled Release, 79(1), 71-79.

24. Patel V, Amiji M, 1996. Preparation and characterization of freeze dried chitosan Poly

(ethylene oxide) hydrogel for site-specific antibiotic delivery in stomach, Pharm. Res., 13,

588-593.

25. Atyabi, F., Sharma, H.L., Mohammad, H.A.H., Fell, J.T., 1996. In vivo evaluation of novel

gastric retentive formulation based on ion exchange resins. J. Control. Release 42, 105–113.

26. Yang, L., Eshraghi, J., Fassihi, R., 1999. A new intragastric delivery system for treatment of

Helicobacter pylori associated gastric ulcer: in vitro evaluation. J. Control. Release 57, 215–

222.

27. Timmermans J, Gansbeke B Van, Moes A J, 1989. Assising by gama scintigraphy in vivo

buoyancy of dosage form developing known size and floating fource profiles as function of

preparation. Proc, 5th Int. Conf. Pharm. Technol, Vol. I, APGI, Paris, 42-51.

28. Sheth P R, Tossounian J, 1984. Hydrodynamically balanced system (HBS): A novel drug

delivery system for oral use. Drug. Dev. Ind. Pharm., (10), 313-339.

29. Zhenphing Wei, Zhanfeng Yu, 2001. Design and Evaluation of two-layer floating tablets for

gastric retention using cisapride as model drug. Drug. Dev. Ind. Pharm., 27(5), 469-474.

30. Soppimeth Kumeresh, Aminabhavi Tejraj, 2001. Development of hollow microspheres as

floating controlled release systems for cardiovascular drugs: Preparation and release

characteristics. Drug. Dev. Ind. Pharm., 27(6), 507-515.

31. Zia H, Chueth H R, Rhodes C T, 1999. Optimization of Sotalol floating and bioadhesive

extended release tablet formulation. Drug. Dev. Ind. Pharm., 21, 1725-1747.

32. Ichikawa M, Kato T, Kawahara M, Watanabe S, Kayano M, 1991. A new multiple unit oral

floating dosage system. II: In vivo evaluation of floating and sustained release characteristics

with P-amino benzoic acid and Isosorbide Dinitrate as model drugs. J. Pharm. Sci., 80, 1153-

1156

33. Srivastava A. K., Wadhwa Saurabh, Mishra B.205.Oral Sustained Delivery of Atenolol from

Floating Matrix Tablets – Formulation and In Vitro Evaluation. Drug. Dev. Ind. Pharm.,

31(4-5), 367-374

1. Coffin; Mark D.; Parr; Alan F. US Patent 5,407,687. Ranitidine solid dosage form, April

1995.

2. Chopra; Sham K.; Nangia; Avinash K.; Lee; David; Molloy; Thomas P. US Patent 5,342,627,

Controlled release device, Aug 1994.

3. Mody; Shri Shirish Bhagwanlal; Doshi; Madhukant Mansukhlal; Joshi; Milind Dattatraya US

Patent 5,853,756, Controlled release formulations of Ranitidine, Dec 1998.

4. Quirk; Christopher W.; Jackson; David A.; Cameron; James M. US Patent 5,456,918,

Ranitidine pharmaceutical compositions, Oct. 1995

5. Davis; Adrian Francis US Patent 5,656,652, Compositions containing histamine H2 receptor

antagonists at low dosage, Aug 1997.

6. Dave BS, Amin AF, Patel MM. 2004. Gastroretentive Drug Delivery System of Ranitidine

Hydrochloride: Formulation and In Vitro Evaluation. AAPS Pharm. Sci.. Tech., 5(2), article

34.

7. Basit Abdul W. and Lacey Larry L., 2001. Colonic metabolism of ranitidine: implications for

its delivery and absorption. Int. J. Pharm. Sci., 227(1-2), 157 – 165.

Streubel A., Siepmann J., Bodmeier R., 2002. Floating microparticles based on low density foam

powder, Int. J. Pharm., 241, 279–292.

2. Streubel A., Siepmann J., Bodmeier R., 2003. Floating matrix tablets based on low density

foam powder: effects of formulation and processing parameters on drug release, European

Journal of Pharmaceutical Sciences, 18, 37–45.

67. El-Kamel, A.H., Sokar, M.S., Naggar, V.F., 2001.Preparation and evaluation of ketoprofen

floating oral drug delivery system. Int. J. Pharm. 220, 13-21.

68. Streubel, A., Siepmann, J., Bodmeier, R., 2002. Floating microparticles based on low

density foam powder. Int J Pharm. 241, 279-292.

69. Kawashima, Y., Niwa, T., Takeuchi, H., Hino, T., Ito, Y., 1991. Preparation of multiple

unit hollow microspheres (microballoons) with acrylic resins containing tranilast and their

drug release characteristics (in vivo). J. Control Rel. 16, 279-290.

70. Sato, Y., Kawashima, Y., 2003. In vivo evaluation of riboflavin-containing microballoons

for floating controlled drug delivery system in healthy human volunteers. J. Control Rel.

93, 39-47.

71. Sato, Y., Kawashima, Y., Takeuchi H.,Yamamoto, H., 2004. In vitro evaluation of floating

and drug releasing behaviors of hollow microspheres (microballoons) prepared by

emulsion solvent diffusion method. Eur. J. Pharm. Biopharm. 57,235-243.

72. Sato, Y., Kawashima, Y., Takeuchi H., Yamamoto, H., 2003. Physicochemical properties

to determine buoyancy of hollow microspheres (microballoons) prepared by emulsion

solvent diffusion method Eur. J. Pharm. Biopharm. 55, 297-304.

73. Kawashima, Y., Takeuchi H., Yamamoto, H., 2004. Design of pH-sensitive microspheres

for colonic delivery of immunosuppressive drug Tacrolimus. Eur. J. Pharm.Biopharm. 58,

37-43.

74. Dashevsky, A., 2004. pH-independent release of basic drug from pellets coated with

extended release polymer dispersion Kollicoat® SR 30 D and enteric polymer dispersion

Kollicoat® MAE 30 DP. Eur. J. Pharm. Biopharm. 58,45-49.

75. Beck, R., 2004. Nanoparticle coated microparticles: preparation and characterization; J.

Microencap. 21, 499 – 512.

76. Kulkarni, A. R., Rudzinski W.E., Tejraj, M., 2001. Microspheres as floating drug delivery

systems to increase gastric retention of drugs. Drug Metabolism Reviews. 33, 149 – 160.

77. Lee, J.H., Park, T.G., Lee, Y.B., Shin, S.C., Choi, H.K., 2001. Effect of adding non-volatile

oil as core material for floating microspheres prepared by emulsion solvent diffusion

method. J. Microencap. 18, 65 – 75.

78. Kumaresh, S., 2001. Development of Hollow Microspheres as Floating Controlled-Release

Systems for Cardiovascular Drugs: Preparation and Release Characteristics. Drug Dev. Ind.

Pharm.27, 507 – 515.

79. Lee, J.H., 1999. Floating microspheres bearing acetohydroxamic acid for treatment of

Helicobacter pylori. J Microencap. 16, 715-729.

80. Lee, J.H., Park, T.G., Choi, H.K., 1999. Development of oral drug delivery system using

floating microspheres. J Microencap. 16, 650-667.

81. Joseph, N.J., Lakshmi, S., Jayakrishnan, A., 2002. A floating type oral dosage form for

piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in

rabbits. J. Control. Rel. 79, 71-79

82. Lai, W.C., Liu, X., Wan P., Heng, S., 2005. Liquid phase coating to produce controlled

release alginate microspheres. J. Microencap. 22, 891-896.

83. Jain, D., Panda, A.K., Majumdar D.K., 2005. Eudragit S100 Entrapped Insulin

Microspheres for Oral Delivery. AAPS Pharm SciTech. 6, Article 16.

84. Haznedar, S., Dortunc, B., 2004. Preparation and in vitro evaluation of Eudragit

microspheres containing acetazolamide. Int. J. Pharm. 269,131-140.

85. Obeidat, W. M., Price, J., 2005. Preparation and evaluation of Eudragit S 100 (methacrylic

acid copolymer) microspheres as pH sensitive release preparations for piroxicam and

theophylline using emulsion-solvent evaporation method. AAPS Annual Meeting and

Exposition.

86. Al-Kassas, R., 2004. Design and in vitro evaluation of gentamicin Eudragit microspheres

intended for intraocular administration. J. Microencap. 21, 71 – 81.

87. Pao, C.W., Huang Y. B.,Chang J.S., 2003. Design and evaluation of sustained release

microspheres of potassium chloride prepared by Eudragit®. Eur. J. Pharm. Sci. 19, 115-

122.

88. Patel, J.K., Patel, R.P., Amin, A.F., Patel, M.M., 2005. Formulation and Evaluation of

Mucoadhesive Glipizide Microspheres. AAPS Pharm Sci. Tech. 6, E49-E55.

89. Curatolo, 1995. Gastric retention system for controlled drug release. US Patent 5 443 843.

22 August.

90. Chowdary, K.P.R., Rao, Y.S., 2003. Design and In Vitro and In Vivo Evaluation of

Mucoadhesive Microcapsules of Glipizide for Oral Controlled Release: A Technical Note.

AAPS Pharm Sci. Tech. 4, Article 3.

91. Bhagwat, 2005. Once-a-day controlled release sulfonylurea formulation. US Patent 6 875

793. 5 April.

92. Garcia, J., Ghaly, E.S., 2001. Evaluation of bioadhesive glipizide spheres and compacts

from spheres prepared by extruder/marumerizer technique. Pharm Dev Technol. 6, 407-

417.

93. Chowdary, K.P.R., Malathi, K., 2004. Ethyl Cellulose Microspheres of Glipizide:

Characterization, In Vitro and In Vivo Evaluation. Indian J. Pharm. Sci. 66, 412-416.

94. Jamzad, S., Fassihi, R., 2006. Development of controlled release low dose class II drug-

Glipizide. Int. J. Pharm. 312, 24-32.

95. Kuczynski, 1996. Dosage form for administering oral hypoglycemic glipizide US Patent 5

545 413. 13 August.

96. Verma, R. K., Garg, S., 2005. Selection of excipients for extended release formulations of

glipizide through drug excipient compatibility testing. J. Pharm. Biomed. Ana. 38, 633-

644.

Chapter 4

1. Histamine H2 antagonists. In: Drug Facts and Comparisons. Fifty Sixth edition. St Louis,

MO: Wolters Kluwer Co; 2002:1192-1197.

2. Somade S, Singh K. Comparative evaluation of wet granulation and direct compression

methods for preparation of controlled release Ranitidine HCL tablets. Indian J Pharm Sci.

2002;64:285.

3. Lauritsen K. Clinical pharmacokinetics of drugs used in treatment of gastrointestinal diseases.

Clinical Pharmacokinetics. 1990;19:11-31, 94-125.

4. Grant S. Ranitidine: updated review of its pharmacodynamic and pharmacokinetic properties

and therapeutic use in peptic ulcer and other allied diseases. Drugs. 1989;37:801-870.

5. Basit Abdul W. and Lacey Larry L., Colonic metabolism of ranitidine: implications for its

delivery and absorption. Int. J. Pharm. Sci. 2001, 227(1-2), 157 – 165.

6. Coffin; Mark D.; Parr; Alan F. US Patent 5,407,687. Ranitidine solid dosage form, April

1995.

7. Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: approach to oral controlled

drug delivery via gastric retention. J. Control. Release 63, 235–259.

8. Chawla G, Bansal A. A means to address regional variability in intestinal drug absorption.

Pharm Tech. 2003;27:50-68.

9. The United States Pharmacopoeia 26 /The National Formulary 21, Ranitidine Hydrochloride,

United States Pharmacopeial Convention, Inc,: 1615 – 1619.

10. Cooper J, Gun C, Powder Flow and Compaction. Inc Carter SJ, Eds. Tutorial Pharmacy. New

Delhi, hidix CBS Publishers and Distributors; 1986:211-233.

11. Shah D, Shah Y, Ramprashad M, Development and Evaluation of Controlled release

Diltiazem hydrochloride microparticles using cross-linked poly (vinyl-alcohol). Drug Dev.

Ind. Pharm; 1997,23(6): 567-574.

12. Aulton ME, Wells TI, Pharmaceutics: The Science of Dosage Form Design. London,

England, Churchill Livingston; 1998:247.

13. Martin A, Micromeretics, In: Martin A, ed. Physical Pharmacy.Baltimores, MD: Lippincott

Williams and Wilkins; 2001:423-454.

14. K Raghuram Reddy, Srinivas Mutalik, Srinivas Reddy, Once-daily sustained release matrix

tablets of Nicorandil: Formulation and in vitro evaluation, AAPS PharmSciTech; 2003,4(4):

1-9.

15. Paulo Costa, Jose Manuel, Sousa Labao, Modeling and comparison of dissolution profiles.

Eur. J. Pharm. Sci; 2001,13: 123-133.

16. Dettmar; Peter William; Dickson; Paul Andrew; Hampson; Frank Chadwick; Jollife; Ian

Gordon; Peers; William; US Patent 6,306,789, Mucoadhesive granules of carbomer suitable

for oral administration of drugs, Oct 1999.

17. Sabinus I. Ofoefule, Sunday E. Okoli and Amarauche Chukwu, Mechanisms behind

sustained release matrix tablets prepared with poly(acrylic) acid polymers, Acta Pharm., 50

(2000), 229-238.

18. Siepmann, J., Streubel, A., Peppas, N.A., 2002. Understanding and predicting drug delivery

from hydrophilic matrix tablets using ‘‘sequential layer’’ model. Pharm. Res. 19, 306–314.

19. Vargas C.L, Ghaly E.S, Kinetic release of theophylline from hydrophilic swellable matrices,

Drug Dev. Ind. Pharm; 1999,25(9): 1045-1050.

20. Rosa M, Zia H, Rhodes T, Dosing and testing in-vitro of bioadhesive and floating drug

delivery system for oral application. Int. J. Pharm; 1994,105:65-70.

21. Baumgartner, S., Smid-Korbar, J.,Vrecer, F., Kristl, J., 1998. Physical and technological

parameters influencing floating properties of matrix tablets based on cellulose ethers. STP

Pharma Sci. 8, 285–290.

22. Timmermans, J., Moës, A.J., 1990. How well do floating dosage forms float? Int. J. Pharm.

62, 207–216.

23. Chatwal, G R., Anand S K., Instrumental Methods of Chemical Analysis (Analytical

chemistry). Fifth revised and Enlarged edition, Himalaya Publishing House: 2.29-2.82, 2005.

Chapter 5

1. Thanoo, B.C., Sunny, M.C., Jayakrishnan, A., 1993. Oral sustained release drug delivery

systems using polycarbonate microspheres capable of floating on gastric fluid. J. Pharm.

Pharmacol. 45, 21–24.

2. Stithit, S., Chen, W., Price, J.C., 1998. Development and characterization of buoyant

theophylline microspheres with near zero order release kinetics. J. Microencapsul. 15 ,

725– 730.

3. Lee, J.H., Park, T.G., Choi, H.K., 1999. Development of oral drug delivery system using

floating microspheres. J. Microencapsul. 16, 715– 729.

4. Whitehead, L., Fell, J.T., Collett, J.H., Sharma, H.L., Smith, A.M., 1998. Floating dosage

forms: in vivo study demonstrating prolonged gastric retention. J. Control. Rel. 55 ,3– 12.

5. Curatolo, 1995. Gastric retention system for controlled drug release. US Patent 5 443

843. 22 August.

6. Jain, S.K., Awasthi, A.M., Jain, N.K., Agrawal, G.P., 2005.Calcium silicate based

microspheres of repaglinide for gastroretentive floating drug delivery: Preparation and in

vitro characterization. J. Control. Rel. 107, 300– 309.

7. Joseph, N.J., Lakshmi, S., Jayakrishnan, A., 2002. A floating-type oral dosage form for

piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in

rabbits. J. Control. Rel. 79, 71–79.

8. Cui, F., Gao, Y., Guan, Y., Yang, L., Zhang, L., Preparation of Roxithromycin-polymeric

microspheres by emulsion solvent diffusion method for taste masking. Int. J. Pharm.,

Accepted Manuscript.

9. Sato, Y., Kawashima, Y.H., Yamamoto, H., 2003. Physicochemical properties to

determine buoyancy of hollow microspheres (microballoons) prepared by emulsion

solvent diffusion method. Eur. J. Pharm. Biopharm. 55,297–304

10. US pharmacopeia 27, 2004.First Supplement. US Pharmacopeial Convention, Rockville,

MD, pp.867

11. Martin, A., Physical Pharmacy: Micromeritics. Philadelphia, PA: Lea & Febiger ; IVth ed

,1993, pp.431– 432.

Chapter 6

1. Sato, Y., Kawashima, Y., Takeuchi H.,Yamamoto, H., 2004. In vitro evaluation of

floating and drug releasing behaviors of hollow microspheres (microballoons) prepared

by emulsion solvent diffusion method. Eur. J. Pharm. Biopharm. 57,235-243.

2. Bhushan, B., 2006. Novel floating dosage form. US Patent Application, 20060013876, 19

January.

3. Jamzad, S., Fassihi, R., 2006. Role of Surfactant and pH on Dissolution Properties of

Fenofibrate and Glipizide: A Technical Note, AAPS Pharm Sci. Tech. 7 Article.2.

4. Patel, S., Patel, J., 2005. Studies in Design and development of chitosan microspheres

using different techniques. M. Pharm. Thesis. North Gujarat University.

5. US pharmacopeia 27, 2004.First Supplement. US Pharmacopeial Convention, Rockville,

MD, pp.867

6. Benet, L.Z., Oie, S., Schwartz, J.B., 1996. Design and optimization of dosage regimens,

pharmacokinetic data, In: Hardman, J.G., Limbird, L.E., Goodman and Gilman’s The

Pharmacological Basis of Therapeutics, Ninth ed., McGraw Hill, New York.

7. Verma, R.K., Garg, S., 2004. Development and evaluation of osmotically controlled oral

drug delivery system of glipizide. Eur. J. Pharm. Biopharm. 57, 513–525

8. Guidance for Industry SUPAC-MR. Modified Release Solid Oral Dosage Forms Scale-

Up and Postapproval Changes: Chemistry, Manufacturing, and Controls. In

vitroDissolution Testing and In Vivo Bioequivalence Documentation.

9. Moore, J., Flanner, H., 1996. Mathematical comparison of dissolution profiles. Pharm

Tech. 20, 64-74.

10. Soppimath, K., Kulkarni, A., Development of Hollow Microspheres as Floating

Controlled Release Systems for Cardiovascular Drugs, Preparation and Release

Characteristics, Drug Dev. Ind. Pharm. 27, 507 – 515.

11. Jain, S.K., Awasthi, A.M., Jain, N.K., 2005. Calcium silicate based microspheres of

repaglinide for gastroretentive floating drug delivery: Preparation and in vitro

characterization. J. Control. Rel. 107, 300– 309.

12. Costa, P., 2001. Modeling and comparision of dissolution profiles. Eur. J. Pharm. Sci.

13, 123-133.